NEW YORK (GenomeWeb News) – Saladax Biomedical has appointed Mark Myslinski to the posts of senior VP and chief commercial officer. Myslinski recently was president and CEO of RedPath Integrated Pathology, where he helped to move the company from research and development to commercialization of a molecular diagnostic assay in a CLIA lab. He also has served as VP of evidence-based medicine at Ortho Clinical Diagnostics and as GM of molecular and cellular diagnostics at Veridex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.